Havelock, Jon
Aaris Henningsen, Anna-Karina
Mannaerts, Bernadette
Arce, Joan-Carles http://orcid.org/0000-0001-7374-5992
,
Funding for this research was provided by:
Ferring Pharmaceuticals
Article History
Received: 22 April 2021
Accepted: 29 June 2021
First Online: 13 July 2021
Declarations
:
: The trials were approved by the applicable ethics committees (i.e., independent ethics committees in Europe, ethics committees in Brazil and Russia, and research ethics boards in Canada) and performed in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Guidelines for Good Clinical Practice, and local regulatory requirements.
: Informed consent was obtained from all participants included in the trials. Informed consent for collection of follow-up data of neonatal outcomes was obtained from each woman and her partner, as applicable per local regulations.
: Consent for publication was obtained from all participants included in the trials as part of the trial informed consent. Trial data were de-identified.
: AKAH has received a consulting fee from Ferring Pharmaceuticals for review of all cases of congenital anomalies in the ESTHER-1 and ESTHER-2 trials. BM and J-CA are employees of Ferring Pharmaceuticals. J-CA has patent applications on follitropin delta granted and pending. The authors report no other relevant financial or non-financial conflicts of interests related to the trials.
: Not applicable.